CN1108290C - Urea derivatives - Google Patents
Urea derivatives Download PDFInfo
- Publication number
- CN1108290C CN1108290C CN98118692A CN98118692A CN1108290C CN 1108290 C CN1108290 C CN 1108290C CN 98118692 A CN98118692 A CN 98118692A CN 98118692 A CN98118692 A CN 98118692A CN 1108290 C CN1108290 C CN 1108290C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- hydrogen atom
- acid
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000003672 ureas Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 83
- 239000002253 acid Substances 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 24
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 15
- 229910052736 halogen Chemical group 0.000 claims abstract description 9
- 150000002367 halogens Chemical group 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 21
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 230000009471 action Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
- 150000001728 carbonyl compounds Chemical class 0.000 claims description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 4
- 238000005336 cracking Methods 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 2
- 238000005804 alkylation reaction Methods 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 9
- 230000008569 process Effects 0.000 abstract description 6
- 239000001257 hydrogen Substances 0.000 abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000000463 material Substances 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- -1 benzylamino ethyl Chemical group 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 10
- 102400000096 Substance P Human genes 0.000 description 10
- 101800003906 Substance P Proteins 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 8
- 239000003513 alkali Substances 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000452 restraining effect Effects 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 238000009834 vaporization Methods 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- REZQBEBOWJAQKS-UHFFFAOYSA-N triacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO REZQBEBOWJAQKS-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HOUUOVXLTFXYSX-UHFFFAOYSA-N [Cl].OC=O Chemical compound [Cl].OC=O HOUUOVXLTFXYSX-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002969 morbid Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 208000009935 visceral pain Diseases 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- AWDUJJOJTFHATJ-UHFFFAOYSA-N ClC(Cl)(Cl)OC=O.[Cl] Chemical compound ClC(Cl)(Cl)OC=O.[Cl] AWDUJJOJTFHATJ-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 description 1
- 101000600903 Homo sapiens Substance-P receptor Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-WPRPVWTQSA-N L-Ephedrine Natural products CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 208000007920 Neurogenic Inflammation Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- YWTSIALSBUJLGP-UHFFFAOYSA-N [Cl].O=COCC1=CC=CC=C1 Chemical compound [Cl].O=COCC1=CC=CC=C1 YWTSIALSBUJLGP-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000001262 acyl bromides Chemical class 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 201000007637 bowel dysfunction Diseases 0.000 description 1
- 230000002213 calciumantagonistic effect Effects 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002746 neurokinin 2 receptor antagonist Substances 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- PGKXDIMONUAMFR-AREMUKBSSA-N saredutant Chemical compound C([C@H](CN(C)C(=O)C=1C=CC=CC=1)C=1C=C(Cl)C(Cl)=CC=1)CN(CC1)CCC1(NC(C)=O)C1=CC=CC=C1 PGKXDIMONUAMFR-AREMUKBSSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000021795 small intestine disease Diseases 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compounds of Formula I wherein R1 is hydrogen or lower alkyl, R2 is hydrogen or halogen and R3 is hydrogen or lower alkoxy, and their pharmacologically acceptable acid addition salts and pharmaceutical compositions containing these compounds and also processes for the preparation of these compounds.
Description
The present invention relates to new urea derivative, one of them nitrogen-atoms is the integral part of a piperazine ring, and another nitrogen-atoms is replaced by the benzylamino ethyl.Being characterized as of the urea derivative that these are new has neurokinin-acceptor-antagonistic properties, and it has the useful mode of action, can be in order to the functional and diseases associated with inflammation of treatment than large mammals, especially human gi-tract.The invention still further relates to medicine that contains these new compounds and the method for preparing these compounds in addition.
The objective of the invention is, develop new active substance in order to treatment gastrointestinal function and diseases associated with inflammation.
Known by European patent application publication No. 655442, bridged piperazine derivatives has neurokinin-antagonistic properties.
Have now found that, one group of new bridged piperazine derivatives is arranged, replaced by the indyl methyl in its 2-position, and the nitrogen-atoms of 4-position is a part that has the substituent urea skeleton of benzylamino ethyl on its piperazine ring, and then the mode of action that they had makes it to be suitable for treating the functional and diseases associated with inflammation of gastrointestinal tract disease.Another feature of material group of the present invention is good tolerability and good oral bioavailability.
So the medicine of purpose of the present invention for new compound shown in the formula I, its physiological tolerance acid salt being provided and can preparing by these compounds,
R wherein
1Be hydrogen atom or low alkyl group, R
2Be hydrogen atom or halogen and R
3Be hydrogen atom or lower alkoxy.
If in the formula I compound substituting group for or contain low alkyl group, then the latter can be straight or branched, and contains 1 to 4, preferred 1 to 2 carbon atom.
If R
1Be low alkyl group, then preferable methyl.
If substituent R
2Be halogen, then preferred fluorine.
If substituent R
3Be lower alkoxy, then preferred methoxyl group.
Preferred R
2Be hydrogen atom and R
3Be the formula I compound of methoxyl group, perhaps preferred R
2Be fluorine and R
3Formula I compound for hydrogen.
1H-indol-3-yl-methyl is preferably placed at the 2R-position of piperazine ring.
Can prepare these compounds according to known method itself.Preparation I compound is especially favourable in accordance with the following methods, wherein
A) with formula II compound
With the reactive carbonyl compound reaction of general formula III,
Wherein Y is that the nucleophilicity that can pass through primary amine or secondary amine is attacked and replaced leavings group, and reaction generates the carbamoyl compounds of general formula I V,
Wherein Y has above-mentioned implication, if by dividing leavings group Y by the formula IV compound that is obtained, can generate a kind of acid, adds a kind of non-nucleophilicity organic bases to formula IV compound, then with formula IV compound and the reaction of general formula V compound,
R wherein
101Be low alkyl group or an amino protecting group, R
2And R
3Have above-mentioned implication, and the protecting group R that then may occur
101Once more the division or
B) with formula II compound and the reaction of general formula VI compound,
R wherein
101, R
2And R
3Has above-mentioned implication, then the protecting group R that may occur
101Division once more,
Randomly with the R that is obtained
1Be the formula I alkylation of hydrogen atom, generate R
1Be the formula I compound of low alkyl group, and randomly the formula I compound that is obtained changed into its acid salt, perhaps acid salt is changed into free formula I compound.
Comparatively suitable is; work-around solution according to method a) at first reacts the reactive carbonyl compound of formula II compound and formula III; transform formamyl-compound of accepted way of doing sth IV, the amine that the latter can directly on-the-spotly, optional add behind a kind of non-nucleophilicity organic bases with formula V reacts.As the leavings group Y in the formula III compound, suitable have a for example halogen, preferred chlorine, and three halogen methoxyl groups, preferred trichlorine methoxyl group perhaps also can be an imidazolyl.Can use phosgene, two-(trichloromethyl)-carbonate (triphosgene), chlorine formic acid-trichloromethyl ester (two phosgene) or carbonyl dimidazoles as the reactive carbonyl compound of formula III.When the formamyl of the amine of formula V and formula IV-compound transformed, leavings group Y was fallen by replaced in the formula IV compound.If by generating a kind of acid at this free group Y that discharges, then comparatively suitable is before transforming with formula V compound, to add a kind of non-nucleophilicity organic bases in formula IV compound.If Y for example is a chlorine, then can be by add the chlorine hydracid constraint that above-mentioned alkali will produce when Y divides.As non-nucleophilicity alkali, be suitable in the reaction mixture solubility organic bases such as tertiary nitrogen alkali being arranged, the alkylating heterocycle of for example nitrogenous N-such as N-low alkyl group-morpholine or N-low alkyl group-piperidines or uncle's formula low-grade alkylamine and pyridine, for example triethylamine, tripropyl amine diisopropyl ethyl amine, pyridine, 4-dimethylaminopyridine, 4-diethyl amino yl pyridines or 4-pyrrolidyl pyridine.The alkali of excessive adding also can be used as solvent and uses.Reaction sequence can be used as single jar and is reflected in the polar protic inert solvent, as in partially halogenated lower hydrocarbon such as methylene dichloride ,-20 ℃ to the temperature between the room temperature, preferably at room temperature carry out.
The conversion of formula II compound and formula VI isocyanate can be according to the work-around solution b of method) carry out in a manner known way.Formula VI compound can be for example generated by transforming with suitable reactive carbonyl compound by the amine of formula V.As reactive carbonyl compound, suitable have a for example formula III compound.Suitable is, at first by the isocyanic ester of the amine preparation formula VI of formula V, then with it directly and formula II compound situ conversion.Can above-mentioned according to method a) preparation I compound finish reaction with single jar of reaction under the given condition.Suitable is to add a kind of sour reagent of tiing up to reaction mixture.As tie up sour reagent suitable above-mentioned non-nucleophilicity alkali arranged.
As amino protecting group, R
101Can consider for example known amino protecting group of chemistry of peptides itself, they can be imported into according to known method itself, and then are divided.Suitable protecting group is for example by J.A.W.McOmie " protecting group in the organic chemistry " Plenum press, 1973 or T.W.Green and P.G.M.Wuts " protecting group in the organic synthesis ", and Wiley and Sons, 1991 are known.
For example suitable protecting group R
101Stable group in acid and alkaline environment is arranged, and they can be divided under the hydrogenolysis condition.What belong to this type of for example has phenyl elementary alkoxy carbonyl such as a benzyloxycarbonyl (below be abbreviated as CbO).As amino protecting group R
101Can the advantageous applications benzyloxycarbonyl, they can be according to known mode itself, and are for example cleaved by the hydrogenation katalysis under, with acquisition R
1Formula I compound for hydrogen atom.Can be in the inert organic solvents under the reaction conditions, as lower aliphatic ether for example in tetrahydrofuran (THF) (below be abbreviated as THF) or the diethyl ether or at low-level chain triacontanol for example in methyl alcohol or the ethanol or at organic acid for example in lower alphatic carboxylic acid such as the acetic acid or in the mixed solution at above-mentioned these solvents and the cracking of carrying out protecting group under the condition that is having hydrogenation catalyst to exist.As hydrogenation catalyst, suitable for example have noble metal catalyst as being stated from the palladium on the gac.Suitable is at room temperature to react.The hydrogen-pressure that is suitable for hydrogenation is between the 2-7 crust, is preferably between the 3-5 crust.
Can be with R
1For the formula I compound of hydrogen atom is converted into R according to known aminoalkyl group method itself
1Formula I compound for low alkyl group.This can be for example by with the reaction of lower aliphatic aldehydes such as formaldehyde, formula I compound is made standard reductive alkylation.Can under the common condition of amine standard reductive alkylation itself, for example under the condition of catalytic hydrogenation, transform.As hydrogenation catalyst, suitable have metal catalyst such as a Raney nickel.As solvent advantageous applications low-level chain triacontanol.Can be at above-mentioned amino protecting group R
101Carry out carrying out catalytic hydrogenation under the condition of hydrogenolysis scission reaction.
Another kind of alkylating method is, under the usual conditions of nucleophilicity substitution reaction, with R
1Be formula I compound and lower aliphatic alkyl halide such as the alkyl bromide or the alkiodide of hydrogen atom, the preferable methyl iodide, alkyl sulfuric ester or alkyl sulfonic ester transform.In polarity matter in inert solvent such as dimethyl formamide (below be abbreviated as DMF), dimethyl sulfoxide (DMSO) (below be abbreviated as DMSO) or acetonitrile, between-20 ℃ to 100 ℃, under the temperature between preferred 60 ℃ to 90 ℃ and tie up in application under the condition of sour reagent and carry out this reaction.As tie up sour reagent suitable for example have above in formula IV compound and the conversion of formula V compound specified organic bases.
Have as the physiological tolerance salt of formula I compound is admissible, itself and mineral acid be the salt of sulfuric acid, phosphoric acid or haloid acid, preferred spirit of salt for example, perhaps with organic acid for example lower aliphatic single-, two-or the salt of tricarboxylic acid such as toxilic acid, fumaric acid, lactic acid, tartrate, citric acid, perhaps with the sulfonic acid for example Phenylsulfonic acid that replaced by halogen or low alkyl group of low alkyl group sulfonic acid such as methanesulfonic or optional its phenyl ring such as the salt of tosic acid.
Can be according to known method itself, by reaction mixture with formula I compound separation and purification.Can acid salt be changed into free alkali according to common mode, and the acid salt that in known manner free alkali is changed into the pharmacology tolerance in case of necessity.
Formula I compound contains a chiral carbon atom, and the carbon atom that promptly has 1H-indol-3-yl-methyl residue is positioned on the 2-position of piperazine basic skeleton.Therefore the form that formula I compound can multiple steric isomer exists.The present invention had both comprised the optical isomer intermixture of formula I compound, comprised its pure isomer again.In the preferred formula I compound, its indole methyl residue is positioned on the 2R-position of piperazine ring.
If the optical isomer intermixture of application formula II initial compounds in formula I compound synthetic, then gained formula I compound is the form of optical isomer intermixture.Set out by initial compounds simple on the stereochemistry, also can obtain formula I compound simple on the stereochemistry, for example by separating in the enterprising circumstances in which people get things ready for a trip spectrum of chiral separation material, perhaps, then in optically active enantiomorph, separate by fractionation crystallization gained diastereoisomeric salt by sour as tartrate or amphene-10-sulfonic acid conversion with suitable optical activity.
Two kinds of enantiomorphs of formula II compound are known by EP-A655422, also can be according to the method or the preparation of method similarly of present patent application explanation.
The amine of formula V can be obtained by the diamino compounds of the formula VII of dual amido protecting,
R wherein
101, R
2And R
3Has above-mentioned implication, R
401Be an amino protecting group, this method is in known manner, divides amino protecting group R by formula VII compound selective ground
401
As amino protecting group R
401, suitable for example generally have by the known amino protecting group of chemistry of peptides, as by above-mentioned source known those.For example, as amino protecting group, R
401In medium at least sour environment, for example by adding tosic acid, trifluoroacetic acid or gasiform or be dissolved in hydrochloric acid in the solvent, splitted group optionally, they are to hydrogenolysis more stable with condition alkalescence.The elementary alkoxy carbonyl that also has side chain for example such as the uncle-butoxy carbonyl (below be abbreviated as BOC) that belong to this type of.R
401Can be preferably uncle-butoxy carbonyl.
Formula VII compound can obtain according to known mode itself, for example passes through the acid amides of reduction general formula VIII,
R wherein
1, R
2, R
3And R
401Have above implication, and, if R
1Be hydrogen atom, then then import a protecting group R
101Reduction reaction can be carried out as reductive agent with compound alkalimetal hydride such as lithium aluminium hydride.Suitable having is organic solvent inert such as lower aliphatic ether, for example mixture of diox, THF or diethyl ether or these solvents under reaction conditions as solvent.Suitable temperature range at-20 ℃ between the boiling temperature of reaction mixture.Preferably at room temperature carry out reduction reaction.
Also can be by aminoacylization, forming the common method of acid amides marshalling (Amidgruppierungen), by with protected omega-amino-carboxylic acid general formula I X, amino,
R wherein
401Have above implication, with the amine generation conversion reaction of general formula X,
R wherein
1, R
2, and R
3Has above implication, the acid amides of preparation formula VIII.As acylating agent, can use acid or its reactive derivatives of formula IX.As reactive derivatives, especially consider the acid of formula IX and chlorine formic acid or with the organic sulfonic acid mixed acid anhydride and acyl chlorides or acylbromide or the mixed ester that form as the Phenylsulfonic acid that replaced by low alkyl group or halogen such as tosic acid of aromatic sulphonic acid for example.Can be in the inert organic solvents under the reaction conditions, at-20 ℃ between the temperature of room temperature, preferably at room temperature carry out acylations.As solvent, the suitable mixture that aromatic hydrocarbon such as benzene or toluene, aliphatic ether such as Anaesthetie Ether, THF Huo diox, partially halogenated lower hydrocarbon such as methylene dichloride or these solvents are arranged.
Suitable is, especially when the carboxylic acid halides of application formula IX acid during as acylating agent, carries out acylations tiing up in the presence of the sour reagent.As tie up sour reagent suitable above-mentioned formamyl-compound and formula V compound specified non-nucleophilicity organic bases when transforming at formula IV arranged.
If the acid itself of using formula IX is as acylating agent, then comparatively suitable is, is suitable in by chemistry of peptides under the condition that known coupling reagent that acid amides generates exists, carries out the conversion reaction of the acid of the amine of formula X and formula IX.As the coupling reagent that promotes as above to generate acid amides with free acid, be they and sour real-world effectiveness, the formation reaction acid derivative, that especially can give an example has: the alkyl carbodiimide, cycloalkyl carbodiimide such as dicyclohexyl carbodiimide or 1-ethyl-3-[(dimethylamino for example)-propyl group]-carbodiimide, di-isopropyl carbodiimide, and carbonyl dimidazoles.Under the temperature between-30 ℃ to+50 ℃, solvent such as halohydrocarbon and/or aromatic solvent as the optional benzene that replaces in, and choose wantonly under the condition that a kind of non-as previously described nucleophilicity nitrogen base of organic compound example of tiing up acid exists, have that to carry out conversion reaction under the condition of coupling reagent comparatively suitable.The acid of formula IX is the amino protected derivative of 2-aminobenzoic acid derivative, known its unprotected form, and can be converted to derivative amino protected according to known method itself.
The compound of formula X is known, perhaps can be prepared by compound known according to known mode itself.
Formula I compound and acid salt thereof have neurokinin (=NK)-characteristic of acceptor-antagonism, be suitable for treating neurokinin participates in morbidity as carrier morbid state.At this, being characterized as of The compounds of this invention has especially favourable selectively acting mode, it is characterized by the affinity that the NK-1-acceptor is had height, and relatively, the NK-2-acceptor had rudimentary affinity.These compounds have good oral action effect in addition.
Based on its mode of action, material group of the present invention is particularly suitable for suppressing those processes that neurokinin such as Substance P participated in conjunction with the NK-1-acceptor.So these matter selective ground are suitable for treating the morbid state that those Substance Ps participate in.Substance P for example works in pain conduction, vomiting, neurogenic inflammation, bladder inflammation, struvite joint disease and asthma.Because it works to gi tract in an advantageous manner, the mode of action of such material is suitable for treating GI functional and diseases associated with inflammation.Prove that in addition these compounds also have certain affinity except that the NK-1-acceptor is had than the high-affinity to the NK-2-acceptor, it is generally acknowledged that these two kinds effect compositions possess favourable synergy to the mechanism that participates in same signs of disease.The functional disease that belongs to the treatment of available The compounds of this invention has, especially so-called " irritable bowel syndrome " (=IBS) or stimulate enteron aisle syndrome, be known disease of lower digestive tract.The IBS The main symptoms is the pleoergy that hypogastralgia, its reason appear as the internal organ afferent nervous system, and stool abnormity, and especially the colonic stool is accelerated by unusual.Because the visceral pain susceptibility to mechanicalness in the gi tract and chemical irritation improves, even caused colon is slightly expanded in the physiological digestive process, for example a small amount of gas produces and slight bulging, does not almost have sensation the normal people, the promptly existing violent visceral pain of patient IBS.The compounds of this invention can advantageously influence some gastrointestinal tract inflammation disease, and the disease that belongs to this type of has, and generally is referred to as diseases associated with inflammation and the ulcerative colitis and the CrohnShi disease of small intestine and the large intestine of IBD (=inflammatory bowel syndrome).The mode of action of these materials is characterized as good biological usability and has the favourable selectivity of neurokinin-acceptor-antagonistic action for undesirable side effect.Determine not have cardiovascular calcium antagonism in the pharmacology test that in the dosage range of retardance NK-1-acceptor, is carried out.
Relate to the preparation embodiment that illustrates later given embodiment number.
Explanation about the pharmacology test method
1. in vitro measure the binding ability of tested object confrontation NK-1-acceptor.
In vitro measure the verify affinity of human NK-1-acceptor of tested object.Mensuration is combined in restraining effect on the NK-1-acceptor to physiological neurokinin (Substance P).
With [
3H]-Substance P carries out acceptor-combination as ligand to be tested.In order to carry out the combination test, the CHO-cell (ovum of=Chinese hamster with various samples, chinese hamsteroocytes) film smear, they can test human NK-1-acceptor, solvent with tagged-ligand is hatched, and hatches throw out and does not contain the additive of tested material or the various concentration of tested material at this.Then in sample, respectively bonded is separated with the free ligand by means of glass fibre-filtration method.Remaining fraction in the filtrate repeatedly with the buffer reagent washing, is then measured the radioactivity of residue fraction in the filtrate with β-scintillometer.Measure the IC of corresponding concentration as corresponding tested material
50, the bonded ligand is squeezed to greatest extent by 50% under this concentration.Numerical value can calculate the corresponding inhibition constant (K of tested material thus
i-value).In this test model, the material of embodiment 1 is to the K of human NK-1-receptor affinity
i-be worth and be 2.1nmol/l.
2. in vitro measure the binding ability of tested object confrontation NK-2-acceptor.
Measure the verify affinity of human NK-2-acceptor of tested object in vitro.Mensuration is to compound S R-48, and 968 are combined in the restraining effect on the NK-2-acceptor.SR-48, the 968th, a kind of compound of synthetic preparation is known specificity NK-2-antagonist.
Use SR-48,968 carry out acceptor-combination as ligand tests.The method of bonding force of in vitro measuring tested object confrontation NK-1-acceptor in working method and the pharmacology test of test is similar.Difference is, uses the film smear sample of various CHO-cells here human NK-2-acceptor is tested.In this test model, below tabulation lattice 1 are enumerated the K of embodiment material to human NK-2-receptor affinity
i-value.Table 1: the verify affinity of human NK-2-acceptor of tested object
3. in vitro measure the functional NK-1-antagonistic action of tested object confrontation guinea pig in vitro tissue
| Embodiment number | K i[μmol/l] |
| 1 2 3 | 0.06 0.05 0.30 |
On the white cavy aortic annulus of the stripped Pirbright-sample in maintaining chemotrophy liquid, in vitro measure the NK-1-acceptor-antagonistic action of tested material.Measure the tested object confrontation excites the aorta sample tension force sexual relaxation of back appearance with NK-1-synergist Substance P restraining effect.
In order to measure the contraction of blood vessel flesh, sample is fixed on the hook, link with single line and force measurement device, contraction each time all is recorded on the register.Make the aorta sample anxiety with the phenyl ephedrine.Then before adding detection material and excite the NK-1-acceptor of sample afterwards with 0.01 μ mol Substance P, cause that tensile relaxes.To add before the detection material and relaxing afterwards represented with percentage ratio respectively.Calculate and produce 50% maximum the concentration (=IC that suppresses
50) as character numerical value, it shows 50% concentration when suppressing tension force to greatest extent and relaxing.
In this test model, below tabulation lattice 2 are enumerated the IC of embodiment material generation during 50% maximum the inhibition
50-value.
Table 2: the functional NK-1-antagonistic action of the stripped cavy tissue of tested object confrontation
4. in vitro measure the material-P-antagonistic action of tested material
| Embodiment number | IC 50[μmol/l] |
| 1 2 3 | 0.001 0.0012 0.0015 |
As the standard test pattern of measuring the pharmacological effect that material-P brings out,, verify the material-P-antagonistic action of tested material by with the caused cavy ypotension of material-P medication.Intravenously (=i.v.) and in the duodenum (=i.d.) with after the tested material medication, measure the restraining effect of the caused blood pressure drops of tested object confrontation Substance P.
To male guinea pig under anesthesia, conduit is inserted in the arteria carotis communis respectively and jugular vein in.Ductus arteriosus is in order to measure blood pressure.Measure with Si Tesemushi 23d/B pressure susceptor.By venous access injected material P and tested material.After 20 minutes balance period, Substance P is annotated with the dosage intravenously group of 50pmol/ animal.Inject tested material then.In the process of the test of intravenously medication, the intravenously dosage of tested material is one group of per 4 to 6 animal of 0.1,0.46 and 1.0 μ mol/kg.The control group physiological saline of corresponding dosage.Inject tested material after 1,15,30,45 and 60 minutes, inject the 50pmol Substance P respectively.Be to be attached to the interior conduit that inserts of duodenum of experimental animal in the test of duodenum innerlich anwenden with above test difference.Tested material passes through catheter drug delivery with the dosage of per 3 to 6 animals 0.046,0.1,0.46,1.0,4.6 and 10.0 μ mol/kg.In these trials, tylose is as vehicle.Measure mean arterial pressure in about 1 minute before material-P medication first and after the medication, and measure the caused maximum blood pressure drops of material-P thus.After 60 minutes, the mean arterial pressure of the control animals of the private Substance P of competitive list treatment and the animal treated with Substance P and tested material, and difference calculates corresponding tested dosages of substance to the restraining effect that maximum blood pressure drops produced that material-P brings out thus, represents with percentage ratio.Corresponding dosage when measuring the blood pressure drops that 50% ground inhibitory substance P brings out is as ED
50
In this test model, the ED of embodiment 1 material after the intravenously medication
50Value is 0.2 μ mol/kg, the ED behind the duodenum innerlich anwenden
50Value is 0.08 μ mol/kg.This i.d. effect can be used as index to the ratio of i.v. effect, and in order to illustrate: this material is suitable for oral medication well, and it preferably plays a role in duodenum.
In same test model, detected the effect of tested object confrontation based on the blood pressure drops of calcium antagonistic properties.In this control animals is with tested material medication, and does not give material-P.Embodiment 1 material (i.v. dosage 1 μ mol/kg, i.d. dosage 10 μ mol/kg) at the most at the most in the dosage range that detects does not have tangible blood pressure drops.This index explanation does not have the side effect of calcium antagonism in this dosage range.The side effect of this amazing small calcium antagonism of The compounds of this invention also can be by invisible spectro standard test pattern, for example the isolated aorta tissue cavy is confirmed.
These materials also can be with common pharmaceutical dosage forms medication.Can there be individual difference in applied dosage, according to different the variation to some extent naturally with institute's applied material of the difference of institute's therapeutic state.In general, be suitable for the mankind and be 0.1 to 80mg activity substance content, especially 1 to 10mg/ single dosage than the drug dose of large mammals medication.
The compounds of this invention can be prepared into solid-state or liquid medicine type with common pharmacopedics adjuvant and/or carrier substance.Solid formulation for example can be oral medication preparation such as tablet, dragee, capsule, pulvis or granula, perhaps also can be suppository.These pharmaceutical preparations can contain commonly used inorganic of pharmacopedics or/and the organic carrier material, and for example talcum powder, lactose or starch can contain pharmacopedics adjuvant commonly used, for example lubricant or tablet disintegrant in addition.The suspension of liquid formulation such as active substance or emulsion can contain thinner commonly used, Ru Shui, oil and/or suspension agent such as polyoxyethylene glycol and similar substance.Other adjuvant be can also add, agent, correctives and class commaterial for example preserved.
Active substance can mix according to known mode own with pharmacopedics adjuvant and/or carrier substance or prepare mutually.In order to prepare solid pharmaceutical dosage forms, for example active substance can be mixed in common mode mutually with adjuvant and/or carrier substance, make granula wet or that do then.Granula or pulvis directly filling become capsule, perhaps are pressed into the tablet ball in common mode.These can make dragee in common mode where necessary.
Following examples can further specify the present invention, but its scope is not limited only to this.
Embodiment 1:(2R)-and 1-[3, two (trifluoromethyl) benzoyls of 5-]-2-(1H-indol-3-yl-methyl-)-4-{2-[N-(2-methoxy-benzyl) amino-ethyl] aminocarboxyl } piperazine
A) uncle 101.5g-butoxy carbonyl glycine is dissolved in the 800ml methylene dichloride under nitrogen atmosphere, and mixes with the 96.5ml triethylamine.Ice-cold slow Dropwise 5 8ml chlorine formic acid ethyl down stirred formed mixture 2 hours under the room temperature, then dripped the solution of 79.8g2-methoxy-benzyl amine in the 400ml methylene dichloride then.Stirred overnight is added 1400ml 15% water-soluble tartaric acid solution then, and was stirred again 30 minutes.Follow with the organic phase separation, through dried over sodium sulfate and vapourisation under reduced pressure.With residuum by diethyl ether/methylene dichloride crystallization and dry in a vacuum.Getting 88.9gN-BOC-C-(2-methoxyl group)-benzylamino glycine is white meal, Fp. (fusing point)=97-97.7 ℃.
B) the above-mentioned products therefrom of 40.0g is dissolved under nitrogen atmosphere in the mixed solution of 600ml toluene and THF (1: 1), and drops to ice-cold 21.0g LiAlH
4In the solution in 500ml THF.Mix liquid under the room temperature and spend the night, ice-cooledly dripping down the mixed solution of 20ml water and 150mlTHF in order, then at room temperature at first adding 20ml 15% water-soluble sodium hydroxide solution then.60ml water then.The solution that forms inhaled from the throw out that generates go and the filtrate vapourisation under reduced pressure.Residuum is absorbed in the 240ml 7.5% water-soluble tartaric acid solution, with the water dichloromethane extraction.Then water is passed through to add the water-soluble sodium hydroxide solution of 200ml10%, make its pH=10, use dichloromethane extraction then 3 times.The methylene dichloride that merges is dry in dried over sodium sulfate, vapourisation under reduced pressure and vacuum.Get 28.0g oiliness N-BOC-N '-(2-methoxyl group)-benzyl-1, it need not purified and can further transform.
C) the above products therefrom of 5.0g is dissolved among the 50mlTHF under nitrogen atmosphere.Add the water-soluble sodium hydroxide solution of 20ml1N.Drip common 3.05g chlorine formic acid benzyl ester and the water-soluble sodium hydroxide solution of 1N simultaneously to formed reaction mixture under ice-cooled, make its pH value be not less than 10.Add to finish to stir under the room temperature of back and spend the night.Then add 150ml methyl-tert-butyl ether, water phase separated, then in order 2 times with 50ml water, 1 time with 50ml 15% water-soluble tartaric acid solution and again 2 times with 50ml water washing organic phase.Organic phase is dry in dried over sodium sulfate, vapourisation under reduced pressure and vacuum then.Get 4.9gN-BOC-N '-(2-methoxyl group)-benzyl-N '-Cbo-1, the 2-diaminoethanes, it need not purified and can further transform.
D) the above products therefrom of 4.8g is dissolved in the 50ml methylene dichloride.Adding 4.4g tosic acid and stirring reaction mixed solution spends the night.Then add the solution of 7.5gNaOH in 75ml water.Organic phase is separated, with 75ml water washing 1 time with through dried over sodium sulfate.With solution vapourisation under reduced pressure and product is dry in a vacuum.Get 3.5g oiliness N-(2-methoxyl group)-benzyl-N-Cbo-1, the 2-diaminoethanes, it need not purified and can further transform.
E), two (trifluoromethyl) benzoyls of 5-with 2.0g (2R)-1-[3]-2-(1H-indol-3-yl-methyl)-piperazine is dissolved in the 100ml methylene dichloride.Successively add 0.6g triphosgene that is dissolved in the 20ml methylene dichloride and the 12.0ml diisopropylethylamine that is dissolved in the 20ml methylene dichloride.Stir formed mixture 1 hour under the room temperature, then drip the above gained aminocompound of 2.8g that is dissolved in the 20ml methylene dichloride.With reaction mixture restir 18 hours, then in order with 10% water-soluble potassium hydrogen sulfate solution, water with wash with saturated potassium bicarbonate solution again.Then methylene dichloride is evaporated down through dried over sodium sulfate and decompression.With residuum process silica gel (eluent: methylene chloride 3: 1) chromatographic separation; get 2.5g oiliness (2R)-1-[3; two (trifluoromethyl) benzoyls of 5-]-2-(1H-indol-3-yl-methyl-)-4-{2-[N-(2-methoxy-benzyl)-N-Cbo-amino-ethyl] aminocarboxyl } piperazine, it need not purified and can further transform.
F) the above products therefrom of 2.5g is dissolved in the 400ml ethanol, and mixes with palladium catalyst that 0.5g 10% is stated from the gac.Then hydrogenation 6 hours under the hydrogen pressures of 4 crust.Elimination catalyzer and decompression are down with solvent evaporation.Process silica gel (eluent: methylene chloride 9: 1) chromatographic separation, get the 1.0g title compound, it is handled with the saturated diethyl ether of HCl-, change into hydrochloride, Fp.=138-140 ℃.
According to above explanation, can also prepare the formula I compound of enumerating in the following table 3:
Table 3:Other compound of formula I
| Embodiment number | R 1 | R 2 | R 3 |
| 2 3 | CH 3 H | H F | OCH 3 H |
Example I:Contain (2R)-1-[3, two (trifluoromethyl) benzoyls of 5-]-2-(1H-indol-3-yl-methyl-)-4-{2-[N-(2-methoxy-benzyl) amino-ethyl]-aminocarboxyl } tablet of piperazine
Contain following composition according to each tablet and prepare tablet: (2R)-1-[3, two (trifluoromethyl) benzoyls of 5-]-2-(1H-indol-3-yl-methyl-)-4-{2-[N-(2-methoxy-benzyl) amino-ethyl]-aminocarboxyl } piperazine-hydrochloride 20mg W-Gum 60mg lactose 135mg gelatin (being 10% solution) 6mg
Active substance, W-Gum and lactose and 10% gelatin solution are concentrated.Paste is ground, formed granula is placed on the suitable sheet metal, dry down at 45 ℃.By pulverizer, mix with following other adjuvant in mixing machine then: talcum powder 5mg Magnesium Stearate 5mg W-Gum 9mg is pressed into the tablet of 240mg then with the exsiccant granula.
Claims (4)
1. compound of Formula I and physiological tolerance acid salt thereof
Wherein
R
1Be hydrogen atom or C
1-C
4Alkyl,
R
2For hydrogen atom or halogen and
R
3Be hydrogen atom or C
1-C
4Alkoxyl group.
2. according to (the 2R)-1-[3 of claim 1, two (trifluoromethyl) benzoyls of 5-]-2-(1H-indol-3-yl-methyl-)-4-{2-[N-(2-methoxy-benzyl) amino-ethyl]-aminocarboxyl } piperazine and physiological tolerance acid salt thereof.
3. contain according to the pharmacological action dosage of claim 1 compound and the pharmacopedics adjuvant commonly used and/or the medicine of carrier substance.
4. the method for preparing compound of Formula I and physiological tolerance acid salt thereof,
Wherein
R
1Be hydrogen atom or C
1-C
4Alkyl,
R
2For hydrogen atom or halogen and
R
3Be hydrogen atom or C
1-C
4Alkoxyl group
It is characterized by,
A) with formula II compound
With the reactive carbonyl compound reaction of general formula III,
Wherein Y is a replaced leavings group of nucleophilicity attack that can pass through primary amine or secondary amine, generates formamyl-compound of general formula I V,
Wherein Y has above-mentioned implication, if can generate a kind of acid by splitting leavings group Y by the formula IV compound that is obtained, adds a kind of non-nucleophilicity organic bases to the formula IV compound that obtains, then with formula IV compound and the reaction of general formula V compound,
R wherein
101Be C
1-C
4Alkyl or an amino protecting group, R
2And R
3Have above-mentioned implication, and the protecting group R that then may occur
101Once more cracking or
B) with formula II compound and the reaction of general formula VI compound,
R wherein
101, R
2And R
3Has above-mentioned implication, then the protecting group R that may occur
101Cracking once more
Randomly with the R that is obtained
1Be the formula I alkylation of hydrogen atom, generate R
1Be C
1-C
4The formula I compound of alkyl, and randomly the formula I compound that is obtained is changed into its physiological tolerance acid salt, perhaps the physiological tolerance acid salt is changed into free formula I compound.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19737274 | 1997-08-27 | ||
| DE19737274.0 | 1997-08-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1218044A CN1218044A (en) | 1999-06-02 |
| CN1108290C true CN1108290C (en) | 2003-05-14 |
Family
ID=7840297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98118692A Expired - Fee Related CN1108290C (en) | 1997-08-27 | 1998-08-25 | Urea derivatives |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US6001833A (en) |
| JP (1) | JP4250228B2 (en) |
| KR (1) | KR19990023605A (en) |
| CN (1) | CN1108290C (en) |
| AR (1) | AR015147A1 (en) |
| AU (1) | AU744104B2 (en) |
| BR (1) | BR9803237B1 (en) |
| CA (1) | CA2245484C (en) |
| CZ (1) | CZ267198A3 (en) |
| DE (1) | DE19824865A1 (en) |
| DZ (1) | DZ2597A1 (en) |
| HK (1) | HK1019604A1 (en) |
| HU (1) | HUP9801889A1 (en) |
| ID (1) | ID20787A (en) |
| IL (1) | IL125885A (en) |
| NO (1) | NO314939B1 (en) |
| NZ (1) | NZ331524A (en) |
| PL (1) | PL193724B1 (en) |
| RU (1) | RU2198883C2 (en) |
| SK (1) | SK111098A3 (en) |
| TR (1) | TR199801683A3 (en) |
| TW (1) | TW520368B (en) |
| UA (1) | UA60300C2 (en) |
| ZA (1) | ZA986721B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10036818A1 (en) | 2000-07-28 | 2002-02-07 | Solvay Pharm Gmbh | New N-Triazolylmethyl-Piperazine Derivatives as Neurokinin Receptor Antagonists |
| UA75425C2 (en) * | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
| ITBO20020198A1 (en) * | 2002-04-12 | 2003-10-13 | Univ Bologna | DERIVATIVES 2, 5 BIS DIAMMINO 1, 4 BENZOCHENIONIC USEFUL FOR THE TREATMENT OF ALZHEIMER DISEASE, METHOD FOR THEIR PREPARATION AND |
| US20070082905A1 (en) * | 2005-05-27 | 2007-04-12 | De Vries Michiel H | Pharmaceutical compositions comprising n-triazolymethyl-piperazine compounds and methods of using same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0655442A1 (en) * | 1993-11-29 | 1995-05-31 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as Tachykinin antagonists |
| WO1996037489A1 (en) * | 1995-05-25 | 1996-11-28 | Fujisawa Pharmaceutical Co., Ltd. | 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists |
| WO1997028141A1 (en) * | 1996-02-02 | 1997-08-07 | Pierre Fabre Medicament | Novel aromatic piperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions, and use thereof as drugs |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9519077D0 (en) * | 1995-09-18 | 1995-11-15 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| JP4189043B2 (en) * | 1996-09-30 | 2008-12-03 | 株式会社資生堂 | N-acyl piperazine derivatives, antibacterial agents, anti-ulcer agents |
-
1998
- 1998-06-04 DE DE19824865A patent/DE19824865A1/en not_active Ceased
- 1998-07-28 TW TW087112327A patent/TW520368B/en not_active IP Right Cessation
- 1998-07-28 ZA ZA986721A patent/ZA986721B/en unknown
- 1998-08-10 AR ARP980103945A patent/AR015147A1/en unknown
- 1998-08-14 KR KR1019980033038A patent/KR19990023605A/en not_active Application Discontinuation
- 1998-08-14 SK SK1110-98A patent/SK111098A3/en unknown
- 1998-08-17 HU HU9801889A patent/HUP9801889A1/en unknown
- 1998-08-21 IL IL12588598A patent/IL125885A/en not_active IP Right Cessation
- 1998-08-21 CZ CZ982671A patent/CZ267198A3/en unknown
- 1998-08-24 JP JP23712898A patent/JP4250228B2/en not_active Expired - Fee Related
- 1998-08-24 NZ NZ331524A patent/NZ331524A/en unknown
- 1998-08-25 CA CA002245484A patent/CA2245484C/en not_active Expired - Fee Related
- 1998-08-25 CN CN98118692A patent/CN1108290C/en not_active Expired - Fee Related
- 1998-08-26 BR BRPI9803237-2A patent/BR9803237B1/en not_active IP Right Cessation
- 1998-08-26 NO NO19983918A patent/NO314939B1/en unknown
- 1998-08-26 DZ DZ980207A patent/DZ2597A1/en active
- 1998-08-26 RU RU98115953/04A patent/RU2198883C2/en not_active IP Right Cessation
- 1998-08-26 PL PL328221A patent/PL193724B1/en not_active IP Right Cessation
- 1998-08-26 UA UA98084604A patent/UA60300C2/en unknown
- 1998-08-26 AU AU81899/98A patent/AU744104B2/en not_active Ceased
- 1998-08-27 US US09/141,623 patent/US6001833A/en not_active Expired - Lifetime
- 1998-08-27 TR TR1998/01683A patent/TR199801683A3/en unknown
- 1998-08-27 ID IDP981171A patent/ID20787A/en unknown
-
1999
- 1999-10-27 HK HK99104799A patent/HK1019604A1/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0655442A1 (en) * | 1993-11-29 | 1995-05-31 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives as Tachykinin antagonists |
| WO1996037489A1 (en) * | 1995-05-25 | 1996-11-28 | Fujisawa Pharmaceutical Co., Ltd. | 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists |
| WO1997028141A1 (en) * | 1996-02-02 | 1997-08-07 | Pierre Fabre Medicament | Novel aromatic piperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions, and use thereof as drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| KR19990023605A (en) | 1999-03-25 |
| JP4250228B2 (en) | 2009-04-08 |
| JPH11140082A (en) | 1999-05-25 |
| RU2198883C2 (en) | 2003-02-20 |
| CZ267198A3 (en) | 1999-03-17 |
| NO983918D0 (en) | 1998-08-26 |
| CN1218044A (en) | 1999-06-02 |
| IL125885A (en) | 2000-08-13 |
| NZ331524A (en) | 2000-02-28 |
| TR199801683A2 (en) | 1999-03-22 |
| HU9801889D0 (en) | 1998-10-28 |
| ZA986721B (en) | 1999-02-02 |
| AU8189998A (en) | 1999-03-11 |
| AR015147A1 (en) | 2001-04-18 |
| HK1019604A1 (en) | 2000-02-18 |
| TW520368B (en) | 2003-02-11 |
| NO983918L (en) | 1999-03-01 |
| TR199801683A3 (en) | 1999-03-22 |
| US6001833A (en) | 1999-12-14 |
| DZ2597A1 (en) | 2003-03-01 |
| SK111098A3 (en) | 1999-05-07 |
| CA2245484A1 (en) | 1999-02-27 |
| NO314939B1 (en) | 2003-06-16 |
| AU744104B2 (en) | 2002-02-14 |
| ID20787A (en) | 1999-03-04 |
| PL193724B1 (en) | 2007-03-30 |
| BR9803237B1 (en) | 2009-05-05 |
| HUP9801889A1 (en) | 2000-11-28 |
| CA2245484C (en) | 2008-04-29 |
| DE19824865A1 (en) | 1999-03-04 |
| UA60300C2 (en) | 2003-10-15 |
| IL125885A0 (en) | 1999-04-11 |
| BR9803237A (en) | 2000-02-08 |
| PL328221A1 (en) | 1999-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW386081B (en) | Opioid compounds | |
| CN1028024C (en) | Tetrazole excitatory amino acid receptor antagonists | |
| EP0356128A2 (en) | 3-(Aminopropyl)methyl phosphinic acid as a therapeutic agent | |
| JP2001502296A (en) | Neuropeptide-Y ligand | |
| JP2002525371A (en) | Benzimidazolinyl piperidine as CGRP ligand | |
| CN101684089A (en) | bicycloester derivative | |
| JPH08119923A (en) | Glycineamide derivative,method of preparing same and medicine containing same | |
| CN112824399B (en) | Immunomodulator | |
| JP4167806B2 (en) | Mevinolin derivatives | |
| CN1509196A (en) | 4(2-butylamino)-2,7-dimethyl-8-(2-methyl(-6-methoxyp-3-yl)pyrazolo-[1,5-A]-1,3,5-triazine as corticotropin releasing factor receptor | |
| CN1167698C (en) | New N-triazolyl methyl piperazine derivate using as neurokinin receptor antagonistic agent | |
| EP0222533A1 (en) | Cis-N-[(2-aminocycloaliphatic)benzene acetamide and -benzamide anticonvulsants | |
| JP2004500351A (en) | Triazospiro compounds having nociceptin receptor affinity | |
| CN1108290C (en) | Urea derivatives | |
| KR20120098720A (en) | Alpha adrenergic receptor modulators | |
| US20140350099A1 (en) | Method of Treating or Preventing Pain | |
| US8076485B2 (en) | Methylphenidate derivatives and uses of them | |
| EP2475361B1 (en) | N-substituted benzenepropanamides for use in the treatment of pain and inflammation | |
| JP3383668B2 (en) | 1-azaadamantane derivatives as 5-HT agonists or antagonists | |
| JP2999557B2 (en) | Use of N-cyclohexylbenzamide to treat intestinal disease | |
| JPH05502231A (en) | Cycloalkyl-substituted glutaramide diuretics | |
| PL182810B1 (en) | N-substituted derivatives of azabicycoheptane, method of obtaining them and their application | |
| JP4028730B2 (en) | Tertiary amino compounds having affinity for opioid receptors | |
| CN1232513C (en) | 1-[1-(hetero) aryl-1-perhydroxyalkylmethyl]-piperazine compound, preparation thereof and pharmaceutics containing it | |
| KR100881040B1 (en) | Medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030514 Termination date: 20120825 |